Iterum Therapeutics (NASDAQ:ITRM) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company’s product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. “

Several other equities analysts have also recently weighed in on the stock. HC Wainwright reiterated a buy rating on shares of Interpace Diagnostics Group in a research note on Friday, June 21st. Royal Bank of Canada increased their price objective on shares of WestJet Airlines from C$20.00 to C$31.00 and gave the stock a sector perform rating in a research note on Wednesday, May 15th. Finally, Needham & Company LLC reiterated a buy rating and issued a $20.00 price objective on shares of Iterum Therapeutics in a research note on Monday, March 25th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Iterum Therapeutics currently has an average rating of Buy and an average target price of $15.75.

ITRM opened at $6.68 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.24. The company’s 50-day moving average is $6.70. Iterum Therapeutics has a 52-week low of $4.70 and a 52-week high of $11.22.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Tuesday, May 14th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.09). The company had revenue of $0.04 million for the quarter. Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 83.95%. As a group, analysts expect that Iterum Therapeutics will post -6.43 EPS for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Story: Momentum Indicator: Relative Strength Index

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.